Apalutamide delays progression of nonmetastatic, castration-resistant prostate cancer
Treatment with an investigational androgen receptor inhibitor significantly delayed the development of metastasis in patients with prostate cancer that had become resistant to standard androgen-deprivation therapy. The results ...
Feb 8, 2018
0
3